U.S. Non-Invasive Cancer Diagnostics Market (2026 - 2033) Size, Share, & Trends Analysis Report By Product (Pathology-based Instruments, Imaging Instruments), By Technology, By Indication, By End User, And Segment Forecasts

Market Segmentation

U.S. Non-invasive Cancer Diagnostics Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
  - Pathology-based Instruments
    - Polymerase Chain Reaction (PCR) Instruments
    - Next-generation Sequencing (NGS) Instruments
    - Microarrays
  - Imaging Instruments
    - Magnetic Resonance Imaging (MRI)
    - Computed Tomography (CT)
    - Positron Emission Tomography (PET)
    - Mammography
    - Others (Ultrasound, etc.)
- Consumables
- Kits & Reagents
U.S. Non-invasive Cancer Diagnostics Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Imaging
- Liquid Biopsy
- Immunoassay
U.S. Non-invasive Cancer Diagnostics Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancer
- Liver Cancer
- Cervical Cancer
- Skin Cancer
- Others (Thyroid Cancer, etc.)
U.S. Non-invasive Cancer Diagnostics End User Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Laboratories
- Others (Academic & Research Institutes, etc.)

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments